Nvelop Therapeutics Set to Present at ESGCT
Nvelop Therapeutics, a pioneering biotechnology firm focused on engineering programmable, non-viral delivery vehicles for therapeutic applications, has exciting news. The company’s team is gearing up to showcase an oral presentation at the esteemed European Society of Gene & Cell Therapy (ESGCT) annual conference. This event is a significant platform for highlighting advances in gene therapy and cellular technologies.
Significance of the Presentation
At this year's conference in Rome, Nvelop aims to unveil updated preclinical findings from its innovative DLVR-M platform. This breakthrough technology emphasizes the capacity of the platform to deliver therapeutic cargo efficiently to cells and tissues that have typically been challenging to target. The presentation promises to underline the programmability and humanization aspects of their delivery vehicle technology, which may pave the way for new avenues in genetic medicine.
Insights From Nvelop's CSO
Melissa Bonner, Ph.D., Nvelop’s Chief Scientific Officer, expressed the team’s enthusiasm: “We’re thrilled to share the latest data on our DLVR-M platform at the ESGCT meeting, particularly showing the emerging advancements of humanized DLVR-M particles.” This reflects Nvelop’s continuous efforts to harness the potential of their platforms to confront existing challenges in delivery systems and to facilitate the development of novel genetic treatments.
Oral Presentation Details
Here are some key details regarding the presentation:
Title: DLVR-M: a novel fully humanized particle for the efficient in vivo delivery of large gene-editing cargoes to human cells.
Date/Time: Friday, October 25, 11:00 a.m. – 1:00 p.m. CEST
Abstract Number: OR106
Session Room: Meeting Room 2
Embargoed Data and Future Plans
The data presented will be under embargo until 8:00 a.m. CEST on the day of the conference. Following the presentation, a detailed copy will be accessible on Nvelop's website for further insights into their findings.
Understanding Nvelop’s DLVR Platforms
Nvelop Therapeutics has developed modular DLVR platforms aimed at overcoming the limitations of existing delivery methods in genetic medicine. The DLVR-X platform originates from the collaborative efforts of co-founder David Liu, Ph.D., at the Broad Institute of MIT and Harvard, and employs engineered virus-like particles designed for efficient gene-editing cargo delivery.
The DLVR-M platform, developed in the laboratories of Dr. J. Keith Joung and Dr. Peter Cabeceiras at Massachusetts General Hospital, utilizes modular structures with reduced viral proteins. Both platforms have shown immense capability to transport a vast array of therapeutic agents validated in in vivo studies, significantly enhancing the specificity and efficiency of treatment approaches.
Introducing Nvelop Therapeutics
Nvelop Therapeutics was established in 2022 with a mission to revolutionize therapeutic delivery systems targeting cells in vivo. The company's innovative platforms allow for highly efficient delivery mechanisms across varied cell types, emphasizing specificity and effectiveness in tackling previously challenging therapeutic targets.
The team is committed to advancing their programmable, non-viral platforms further, seeking to address a range of previously undruggable diseases through strategic collaborations and clinical pipelines. With robust backing from prominent investors in the life sciences sector, Nvelop is positioned for substantial growth and innovation in the realm of genetic medicine.
Frequently Asked Questions
What is the focus of Nvelop Therapeutics?
Nvelop focuses on developing non-viral delivery systems for therapeutic applications, aiming to improve the efficacy and specificity of genetic medicines.
When and where is Nvelop's presentation taking place?
Nvelop's presentation is set for October 25 at the ESGCT conference in Rome.
What is the DLVR-M platform?
DLVR-M is a modular platform designed to facilitate the delivery of gene-editing cargoes, highlighting programmability and humanized delivery systems.
Who are the co-founders of Nvelop Therapeutics?
Nvelop was co-founded by David Liu and J. Keith Joung, prominent figures in the gene-editing field.
How can someone learn more about Nvelop Therapeutics?
For more information, interested parties can visit Nvelop's website or follow the company on social media platforms.
